|
WO2021048135A1
|
|
Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
|
|
WO2021018869A1
|
|
1,2,4-oxadiazol-5-one derivatives for the treatment of cancer
|
|
WO2020058405A1
|
|
Pharmaceutical combinations for use in the treatment of neoplastic diseases
|
|
AU2019313525A1
|
|
Methods for purifying isavuconazonium sulfate
|
|
WO2019115709A1
|
|
Mitochondrial inhibitors for the treatment of proliferation disorders
|
|
EP3713565A1
|
|
Pharmaceutical combinations for use in the treatment of neoplastic diseases
|
|
WO2019072978A1
|
|
Mitochondrial inhibitors for the treatment of proliferation disorders
|
|
AR113437A1
|
|
MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS
|
|
EP3624790A1
|
|
Novel dosage principle for drugs useful for treating neoplastic diseases
|
|
MX2019012257A
|
|
Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof.
|
|
AU2017289318A1
|
|
Mitochondrial inhibitors for the treatment of proliferation disorders
|
|
AU2016341399A1
|
|
Use of EB1 as a biomarker of drug response
|
|
AU2016217874A1
|
|
Substituted mono- and polyazanaphthalene derivatives and their use
|
